Leap Therapeutics (NASDAQ:LPTX) Cut to Hold at Baird R W
Leap Therapeutics (NASDAQ:LPTX – Get Free Report) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports. Several other ...
Hosted on MSN1d
HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)
Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
American Association of Individual Investors3d
Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%
Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) ...
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...
The Pharma Letter1d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Apple downgraded, Rivian initiated: Wall Street's top analyst calls
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Despite the set back in advanced gastric cancer, the company announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab (DKN-01) in combination with bevacizumab and ...